The time to re-enter the RNAi revolution is now,” said Robert Nelsen, the managing director of Arch, which led the Series A funding round for City Therapeutics.
City Therapeutics, Inc. announced its launch today with a vision to lead the future of RNA interference (RNAi)-based medicine. City Therapeuticstm aims to harness next-generation engineering of small ...
MicroRNAs, or miRNAs, are small, non-coding molecules of RNA. They play an important role in determining how much messenger RNA (mRNA), which carries genetic information, eventually gets translated ...
The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.